23.06

6.60% -1.63

Nurix Therapeutics Inc (NRIX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$24.69

Offen:

$24.86

24-Stunden-Volumen:

1.55M

Relative Volume:

0.83

Marktkapitalisierung:

$2.39B

Einnahmen:

$71.78M

Nettoeinkommen (Verlust:

$-295.28M

KGV:

-7.2982

EPS:

-3.1597

Netto-Cashflow:

$-271.85M

1W Leistung:

-3.80%

1M Leistung:

+50.72%

6M Leistung:

+19.48%

1J Leistung:

+82.00%

1-Tages-Spanne:

$22.33

$24.86

1-Wochen-Bereich:

$22.33

$24.95

52-Wochen-Spanne:

$8.195

$24.95

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Firmenname

Nurix Therapeutics Inc

Sektor

Healthcare (1096)

Branche

Biotechnology (616)

Telefon

(415) 660-5320

Adresse

1600 SIERRA POINT PKWY, BRISBANE

Mitarbeiter

357

Twitter

Nächster Verdiensttermin

2026-07-08

Neueste SEC-Einreichungen

NRIX's Discussions on Twitter

Compare NRIX vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NRIX Nurix Therapeutics Inc	23.06	2.39B	71.78M	-295.28M	-271.85M	-3.1597
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-08	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-11-24	Fortgesetzt	Truist	Buy
2025-10-21	Eingeleitet	Mizuho	Outperform
2025-03-17	Eingeleitet	Leerink Partners	Market Perform
2024-12-10	Eingeleitet	BTIG Research	Buy
2024-12-06	Eingeleitet	BMO Capital Markets	Outperform
2024-10-24	Eingeleitet	UBS	Buy
2024-10-11	Eingeleitet	Jefferies	Buy
2024-09-06	Fortgesetzt	Robert W. Baird	Outperform
2024-07-31	Eingeleitet	Truist	Buy
2023-06-26	Fortgesetzt	Oppenheimer	Outperform
2023-03-09	Eingeleitet	Barclays	Overweight
2023-02-28	Eingeleitet	Oppenheimer	Outperform
2022-10-11	Eingeleitet	Morgan Stanley	Equal-Weight
2022-05-31	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-02-10	Eingeleitet	Wells Fargo	Equal Weight
2021-12-29	Eingeleitet	H.C. Wainwright	Buy
2021-10-14	Eingeleitet	SVB Leerink	Outperform
2021-06-04	Fortgesetzt	Robert W. Baird	Outperform
2021-04-30	Fortgesetzt	Piper Sandler	Overweight
2021-04-30	Eingeleitet	RBC Capital Mkts	Outperform
2021-04-14	Eingeleitet	Berenberg	Buy
2020-11-19	Eingeleitet	Robert W. Baird	Outperform
2020-08-18	Eingeleitet	JP Morgan	Overweight
2020-08-18	Eingeleitet	Needham	Buy
2020-08-18	Eingeleitet	Piper Sandler	Overweight
2020-08-18	Eingeleitet	Stifel	Buy

Alle ansehen

Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten

Jul 10, 2026

NRIX Maintained by HC Wainwright & Co. -- Price Target Raised to $34 - GuruFocus

Jul 10, 2026

Enterprise value to EBITDA forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView

Jul 10, 2026

Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 32% Upside - TradingView

Jul 10, 2026

NRIX Maintained by Truist Securities -- Price Target Raised to $34.00 - GuruFocus

Jul 10, 2026

RBC Capital Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $33 - Moomoo

Jul 10, 2026

A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $28 to $40 - Moomoo

Jul 10, 2026

Nurix stock price target raised to $34 by H.C. Wainwright By Investing.com - Investing.com India

Jul 10, 2026

Mizuho raises Nurix stock price target to $34 on Roche deal By Investing.com - Investing.com South Africa

Jul 10, 2026

Nurix stock price target raised to $34 by H.C. Wainwright - Investing.com UK

Jul 10, 2026

Baird reiterates Nurix stock Outperform rating at $33 target By Investing.com - Investing.com India

Jul 10, 2026

Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.25, Implies 31% Upside - TradingView

Jul 10, 2026

Russell Growth Index Additions Could Be A Game Changer For Nurix Therapeutics (NRIX) - Sahm

Jul 10, 2026

Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.6% After Earnings Miss - MarketBeat

Jul 10, 2026

Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $40.00 - MarketBeat

Jul 10, 2026

Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $33.00 at Royal Bank Of Canada - MarketBeat

Jul 10, 2026

NRIX Reiterates by BTIG -- Price Target Maintained at $32 - GuruFocus

Jul 10, 2026

BTIG Research Reaffirms "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat

Jul 10, 2026

Needham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat

Jul 10, 2026

RBC Capital Raises Nurix Therapeutics Price Target to $33 From $30, Maintains Outperform Speculative Risk Rating - marketscreener.com

Jul 10, 2026

Nurix Therapeutics Reports Q2 Loss, Revenue Falls Short Of Expectations - Bitcoin World

Jul 10, 2026